SG11202005799XA - DIARYL SUBSTITUTED 5,5-FUSED RING COMPOUNDS AS C5aR INHIBITORS - Google Patents
DIARYL SUBSTITUTED 5,5-FUSED RING COMPOUNDS AS C5aR INHIBITORSInfo
- Publication number
- SG11202005799XA SG11202005799XA SG11202005799XA SG11202005799XA SG11202005799XA SG 11202005799X A SG11202005799X A SG 11202005799XA SG 11202005799X A SG11202005799X A SG 11202005799XA SG 11202005799X A SG11202005799X A SG 11202005799XA SG 11202005799X A SG11202005799X A SG 11202005799XA
- Authority
- SG
- Singapore
- Prior art keywords
- fused ring
- ring compounds
- diaryl substituted
- c5ar inhibitors
- c5ar
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Dermatology (AREA)
- Pulmonology (AREA)
- Dispersion Chemistry (AREA)
- Psychiatry (AREA)
- Hematology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Rheumatology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Transplantation (AREA)
- Diabetes (AREA)
- Otolaryngology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762609844P | 2017-12-22 | 2017-12-22 | |
| PCT/US2018/066677 WO2019126431A1 (en) | 2017-12-22 | 2018-12-20 | DIARYL SUBSTITUTED 5,5-FUSED RING COMPOUNDS AS C5aR INHIBITORS |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202005799XA true SG11202005799XA (en) | 2020-07-29 |
Family
ID=66950014
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202005799XA SG11202005799XA (en) | 2017-12-22 | 2018-12-20 | DIARYL SUBSTITUTED 5,5-FUSED RING COMPOUNDS AS C5aR INHIBITORS |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US10759807B2 (en) |
| EP (1) | EP3728202A4 (en) |
| JP (1) | JP7253557B2 (en) |
| KR (1) | KR20200110656A (en) |
| CN (1) | CN111788184B (en) |
| AU (1) | AU2018388657C1 (en) |
| BR (1) | BR112020012374A2 (en) |
| CA (1) | CA3086111A1 (en) |
| IL (1) | IL275516B2 (en) |
| MA (1) | MA51327A (en) |
| MX (1) | MX2020006460A (en) |
| NZ (1) | NZ765590A (en) |
| SG (1) | SG11202005799XA (en) |
| TW (1) | TWI817968B (en) |
| WO (1) | WO2019126431A1 (en) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10683294B2 (en) | 2017-05-31 | 2020-06-16 | Chemocentryx, Inc. | 5-5 fused rings as C5a inhibitors |
| JP7141130B2 (en) | 2017-05-31 | 2022-09-22 | ケモセントリックス，インコーポレイティド | 6-5 Fused Rings as C5a Inhibitors |
| US11542256B2 (en) | 2017-09-03 | 2023-01-03 | Angion Biomedica Corp. | Vinylheterocycles as Rho-associated coiled-coil kinase (ROCK) inhibitors |
| SG11202005799XA (en) | 2017-12-22 | 2020-07-29 | Chemocentryx Inc | DIARYL SUBSTITUTED 5,5-FUSED RING COMPOUNDS AS C5aR INHIBITORS |
| US10828285B2 (en) * | 2017-12-22 | 2020-11-10 | Chemocentryx, Inc. | Diaryl substituted 6,5-fused ring compounds as C5aR inhibitors |
| CA3095184A1 (en) * | 2018-04-02 | 2019-10-10 | Chemocentryx, Inc. | Prodrugs of fused-bicyclic c5ar antagonists |
| BR112021022682A2 (en) | 2019-05-14 | 2022-02-22 | Provention Bio Inc | Methods and compositions for preventing type 1 diabetes |
| CN112300169B (en) * | 2019-07-26 | 2022-03-04 | 上海美迪西生物医药股份有限公司 | Pyrrolopyrazole derivative, preparation method and medical application thereof |
| EP4005638A4 (en) * | 2019-07-29 | 2023-07-05 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
| KR20220118419A (en) | 2019-12-19 | 2022-08-25 | 액티브 바이오테크 에이비 | Compounds for the treatment of ocular diseases associated with excessive angiogenesis |
| WO2021222971A1 (en) * | 2020-05-06 | 2021-11-11 | Dimerix Bioscience Ltd | Treatment for virus induced acute respiratory distress syndrome |
| US20230165838A1 (en) * | 2020-05-06 | 2023-06-01 | Dimerix Bioscience Ltd. | Treatment for acute respiratory distress syndrome |
| JP2023525081A (en) * | 2020-05-07 | 2023-06-14 | エーシー・イミューン・エス・アー | Novel compounds for diagnostics |
| US20220047592A1 (en) * | 2020-08-13 | 2022-02-17 | Chemocentryx, Inc. | METHODS OF TREATING RESPIRATORY DISEASES USING C5a INHIBITORS |
| CA3192880A1 (en) | 2020-10-28 | 2022-05-05 | Chemocentryx, Inc. | Methods of treating hidradenitis suppurativa |
| KR20230149402A (en) * | 2022-04-20 | 2023-10-27 | 목포대학교산학협력단 | Composition for preventing and treating valve calcification |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR0113176A (en) * | 2000-08-10 | 2003-06-17 | Pharmacia Italia Spa | Bicyclo-pyrazole compounds, pharmaceutical compositions comprising the compounds, use of the compounds in the manufacture of medicaments, processes for the preparation of the compounds, combinatorial chemical collection and methods for the treatment of mammals including humans using the compounds. |
| BR0017338A (en) | 2000-09-29 | 2004-04-27 | Neurogen Corp | Compound, process for preparing a compound, pharmaceutical composition, and methods for treating a patient, for inhibiting c5a promoted cell chemotaxis, for localizing c5a receptors in a tissue, and for reducing the severity or frequency of one or more inflammatory transplant sequelae organ |
| JP4196678B2 (en) | 2001-04-26 | 2008-12-17 | 味の素株式会社 | Heterocyclic compounds |
| ITMI20012025A1 (en) | 2001-09-28 | 2003-03-28 | Dompe Spa | QUATERNARY AMMONIUM SALTS OF OMEGA-AMINO ALKYLAMIDS OF R 2-ARY-PROPIONIC ACIDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM |
| WO2003082826A1 (en) | 2002-03-28 | 2003-10-09 | Neurogen Corporation | Substituted biaryl amides as c5a receptor modulators |
| EP1487798A4 (en) | 2002-03-28 | 2005-07-13 | Neurogen Corp | Substituted tetrahydroisoquinolines as c5a receptor modulators |
| JP2005530719A (en) | 2002-03-29 | 2005-10-13 | ニューロジェン コーポレーション | Combination therapy for the treatment of conditions with pathogenic inflammatory components |
| US7166619B2 (en) | 2002-08-14 | 2007-01-23 | Ppd Discovery , Inc. | Prenylation inhibitors and methods of their synthesis and use |
| US7169775B2 (en) | 2002-08-21 | 2007-01-30 | Neurogen Corporation | Amino methyl imidazoles as C5a receptor modulators |
| ATE552253T1 (en) | 2002-11-08 | 2012-04-15 | Novartis Int Pharm Ltd | 3-SUBSTITUTED-6-ARYL-PYRIDINE DERIVATIVES AS LIGANDS FOR C5A RECEPTORS |
| US7145012B2 (en) | 2003-04-23 | 2006-12-05 | Pfizer Inc. | Cannabinoid receptor ligands and uses thereof |
| US20040214856A1 (en) | 2003-04-23 | 2004-10-28 | Pfizer Inc | Cannabinoid receptor ligands and uses thereof |
| AU2003902354A0 (en) | 2003-05-15 | 2003-05-29 | Harkin, Denis W. | Treatment of haemorrhagic shock |
| WO2005007087A2 (en) | 2003-07-03 | 2005-01-27 | Neurogen Corporation | Substituted (heterocycloalkyl)methyl azole derivatives as c5a receptor modulators |
| CN101318962A (en) * | 2003-09-17 | 2008-12-10 | 詹森药业有限公司 | Fused heterocyclic compounds |
| US7906528B2 (en) | 2004-10-05 | 2011-03-15 | Novartis International Pharmaceutical Ltd. | Pyrrolo-pyridine, pyrrolo-pyrimidine and related heterocyclic compounds |
| US7598255B2 (en) | 2005-08-04 | 2009-10-06 | Janssen Pharmaceutica Nv | Pyrimidine compounds as serotonin receptor modulators |
| WO2007051062A2 (en) | 2005-10-28 | 2007-05-03 | Chemocentryx, Inc. | Substituted dihydropyridines and methods of use |
| WO2008024978A2 (en) * | 2006-08-24 | 2008-02-28 | Serenex, Inc. | Tetrahydroindolone and tetrahydroindazolone derivatives |
| PE20110063A1 (en) | 2008-06-20 | 2011-02-16 | Genentech Inc | DERIVATIVES OF [1, 2, 4] TRIAZOLO [1, 5-a] PYRIDINE AS JAK INHIBITORS |
| EP3078658B1 (en) | 2008-12-22 | 2019-04-10 | ChemoCentryx, Inc. | C5ar antagonists |
| US20110275639A1 (en) | 2008-12-22 | 2011-11-10 | Chemocentryx, Inc. | C5aR ANTAGONISTS |
| DK2585064T3 (en) | 2010-06-24 | 2017-07-24 | Chemocentryx Inc | C5aR antagonists |
| GB201016880D0 (en) * | 2010-10-07 | 2010-11-17 | Riotech Pharmaceuticals Ltd | Phosphodiesterase inhibitors |
| US8846656B2 (en) | 2011-07-22 | 2014-09-30 | Novartis Ag | Tetrahydropyrido-pyridine and tetrahydropyrido-pyrimidine compounds and use thereof as C5a receptor modulators |
| WO2014028805A1 (en) | 2012-08-16 | 2014-02-20 | Janssen Pharmaceutica Nv | Pyrrolopyrazoles as n-type calcium channel blockers |
| CN103421006B (en) | 2013-08-18 | 2016-06-22 | 上海师范大学 | 2,3,5,7-tetra-substituted dihydro pyrazol hexahydropyridine derivant and its preparation method and application |
| GB201321746D0 (en) | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic agents |
| MA44629A (en) | 2016-04-04 | 2021-03-24 | Chemocentryx Inc | SOLUBLE C5AR ANTAGONISTS |
| JP7141130B2 (en) | 2017-05-31 | 2022-09-22 | ケモセントリックス，インコーポレイティド | 6-5 Fused Rings as C5a Inhibitors |
| US10683294B2 (en) * | 2017-05-31 | 2020-06-16 | Chemocentryx, Inc. | 5-5 fused rings as C5a inhibitors |
| US10828285B2 (en) * | 2017-12-22 | 2020-11-10 | Chemocentryx, Inc. | Diaryl substituted 6,5-fused ring compounds as C5aR inhibitors |
| SG11202005799XA (en) | 2017-12-22 | 2020-07-29 | Chemocentryx Inc | DIARYL SUBSTITUTED 5,5-FUSED RING COMPOUNDS AS C5aR INHIBITORS |
| CA3095184A1 (en) | 2018-04-02 | 2019-10-10 | Chemocentryx, Inc. | Prodrugs of fused-bicyclic c5ar antagonists |
-
2018
- 2018-12-20 SG SG11202005799XA patent/SG11202005799XA/en unknown
- 2018-12-20 US US16/226,898 patent/US10759807B2/en active Active
- 2018-12-20 JP JP2020534276A patent/JP7253557B2/en active Active
- 2018-12-20 NZ NZ765590A patent/NZ765590A/en unknown
- 2018-12-20 WO PCT/US2018/066677 patent/WO2019126431A1/en unknown
- 2018-12-20 MA MA051327A patent/MA51327A/en unknown
- 2018-12-20 AU AU2018388657A patent/AU2018388657C1/en active Active
- 2018-12-20 BR BR112020012374-9A patent/BR112020012374A2/en unknown
- 2018-12-20 KR KR1020207020946A patent/KR20200110656A/en not_active Application Discontinuation
- 2018-12-20 CA CA3086111A patent/CA3086111A1/en active Pending
- 2018-12-20 CN CN201880083298.3A patent/CN111788184B/en active Active
- 2018-12-20 MX MX2020006460A patent/MX2020006460A/en unknown
- 2018-12-20 IL IL275516A patent/IL275516B2/en unknown
- 2018-12-20 EP EP18890087.2A patent/EP3728202A4/en active Pending
- 2018-12-21 TW TW107146418A patent/TWI817968B/en active
-
2020
- 2020-07-27 US US16/939,667 patent/US11485737B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| AU2018388657B2 (en) | 2022-12-01 |
| EP3728202A4 (en) | 2021-05-26 |
| CN111788184A (en) | 2020-10-16 |
| IL275516B2 (en) | 2023-12-01 |
| BR112020012374A2 (en) | 2020-11-24 |
| US11485737B2 (en) | 2022-11-01 |
| NZ765590A (en) | 2024-01-26 |
| TWI817968B (en) | 2023-10-11 |
| EP3728202A1 (en) | 2020-10-28 |
| MX2020006460A (en) | 2020-11-06 |
| US20190194208A1 (en) | 2019-06-27 |
| JP2021506900A (en) | 2021-02-22 |
| IL275516B1 (en) | 2023-08-01 |
| US20210009596A1 (en) | 2021-01-14 |
| TW201934552A (en) | 2019-09-01 |
| IL275516A (en) | 2020-08-31 |
| MA51327A (en) | 2021-05-26 |
| JP7253557B2 (en) | 2023-04-06 |
| CA3086111A1 (en) | 2019-06-27 |
| KR20200110656A (en) | 2020-09-24 |
| AU2018388657C1 (en) | 2023-03-23 |
| RU2020124094A (en) | 2022-01-24 |
| US10759807B2 (en) | 2020-09-01 |
| CN111788184B (en) | 2023-12-22 |
| WO2019126431A1 (en) | 2019-06-27 |
| AU2018388657A1 (en) | 2020-07-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL275516A (en) | Diaryl substituted 5,5-fused ring compounds as c5ar inhibitors | |
| IL275500A (en) | Diaryl substituted 6,5-fused ring compounds as c5ar inhibitors | |
| IL282468A (en) | 2- amino-n-heteroaryl-nicotinamides as nav1.8 inhibitors | |
| EP3389783A4 (en) | Novel compounds as indoleamine 2,3-dioxygenase inhibitors | |
| ZA201700737B (en) | Cyclohexyl-ethyl substituted diaza- and triaza-tricyclic compounds as indole-amine-2,3-dioxygenase (ido) antagonists for the treatment of cancer | |
| SI3397631T1 (en) | Substituted 3-azabicyclo(3.1.0)hexanes as ketohexokinase inhibitors | |
| EP3160940A4 (en) | Substituted benzene and 6,5-fused bicyclic heteroaryl compounds | |
| WO2016044463A3 (en) | Mk2 inhibitors and uses thereof | |
| EP3504185A4 (en) | Novel substituted n'-hydroxycarbamimidoyl-1,2,5-oxadiazole compounds as indoleamine 2,3-dioxygenase (ido) inhibitors | |
| EP3703692A4 (en) | Novel substituted tetrahydroquinolin compounds as indoleamine 2,3-dioxygenase (ido) inhibitors | |
| IL271399A (en) | Methods for the preparation of 1,3-benzodioxole heterocyclic compounds | |
| EP3585774A4 (en) | Novel substituted sulfoximine compounds as indoleamine 2,3-dioxygenase (ido) inhibitors | |
| EP3694502A4 (en) | Novel substituted cyclobutylbenzene compounds as indoleamine 2,3-dioxygenase (ido) inhibitors | |
| EP3709986A4 (en) | Novel substituted biaryl compounds as indoleamine 2,3-dioxygenase (ido) inhibitors | |
| EP3661909A4 (en) | Novel substituted phenyl compounds as indoleamine 2,3-dioxygenase (ido) inhibitors | |
| HK1256825A1 (en) | Solid forms of substituted 5,6-dihydro-6-phenylbenzo[f]isoquinolin-2-amine compounds | |
| EP3694503A4 (en) | Novel substituted cyclobutylpyridine and cyclobutylpyrimidine compounds as indoleamine 2,3-dioxygenase (ido) inhibitors | |
| EP3694506A4 (en) | Novel substituted phenyloxetane and phenyltetrahydrofuran compounds as indoleamine 2,3-dioxygenase (ido) inhibitors | |
| SG11202010661SA (en) | Oxo-substituted compound | |
| EP3661910A4 (en) | Novel substituted pyridine compounds as indoleamine 2,3-dioxygenase (ido) inhibitors | |
| EP3600299A4 (en) | Novel substituted n'-hydroxycarbamimidoyl-1,2,5-oxadiazole compounds as indoleamine 2,3-dioxygenase (ido) inhibitors | |
| PT3515454T (en) | Crystalline polymorphic form of 3-hydroxy-4,5-bis-benzyloxy-6-benzyloxymethyl-2-phenyl-2-oxo-2lambda5-[1,2]oxaphosphinane | |
| EP3806814A4 (en) | Photostabilizing compounds, compositions, and methods | |
| GB201714439D0 (en) | Organic intermediate 1,6-cyclohexanedione synthesis method | |
| MY174415A (en) | Salt form, crystal form and intermediate of 1,2,5-thiadiazolidine-1,1-dioxide and preparation method thereof |